The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Echeverry, Ramiro ^a   Wu, Fang ^a   Haile, Woldeab B ^a   Wu, Jialing ^a,b   Yepes, Manuel ^a,c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Tianjin Huanhu Hospital   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Whitehead Biomedical Research Building ^*  (United States)

Author keywords

Cerebral ischemia; Inflammation; Ischemic tolerance; Preconditioning; TWEAK

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN BCL 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; GLUCOSE; NEUROPROTECTIVE AGENT; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; ANOXIA; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; CEREBRAL ARTERY DISEASE; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; METHODOLOGY; MOUSE MUTANT; NERVE CELL; NICK END LABELING; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

ANIMALS; ANOXIA; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE; IN SITU NICK-END LABELING; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC PRECONDITIONING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84857741136     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-45     Document Type: Article

References (47)

1. Kirino T, Nakagomi T, Kanemitsu H, Tamura A. Ischemic tolerance. Adv Neurol 1996, 71:505-511.
2. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab 2002, 22:1283-1296.
3. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, De SG, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Michael HP, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J, Roger VL, Turner MB. Executive summary: heart disease and stroke statistics-2011 update: a report from the American heart association. Circulation 2011, 123:459-463.
4. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-32410. 10.1074/jbc.272.51.32401, 9405449.
5. Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005, 166:511-520. 10.1016/S0002-9440(10)62273-0, 1602337, 15681834.
6. Yepes M. Tweak and FN14 in central nervous system health and disease. Front Biosci 2007, 12:2772-2781.
7. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837-846. 10.1016/S1074-7613(01)00232-1, 11728344.
8. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999, 274:8455-8459. 10.1074/jbc.274.13.8455, 10085077.
9. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002, 299:488-493. 10.1016/S0006-291X(02)02670-0, 12445828.
10. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23:594-600. 10.1161/01.ATV.0000062883.93715.37, 12615668.
11. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, Hoelzinger DB, Beaudry C, Coons SW, Berens ME. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003, 162:1313-1321. 10.1016/S0002-9440(10)63927-2, 1851233, 12651623.
12. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003, 278:32317-32323. 10.1074/jbc.M302518200, 12794080.
13. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 2000, 32:102-107. 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U, 10975915.
14. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, Dayer JM. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4:126-133. 10.1186/ar388, 83846, 11879548.
15. Xu H, Okamoto A, Ichikawa J, Ando T, Tasaka K, Masuyama K, Ogawa H, Yagita H, Okumura K, Nakao A. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 2004, 318:422-427. 10.1016/j.bbrc.2004.04.036, 15120617.
16. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004, 68:396-399. 10.1253/circj.68.396, 15056843.
17. Jin L, Nakao A, Nakayama M, Yamaguchi N, Kojima Y, Nakano N, Tsuboi R, Okumura K, Yagita H, Ogawa H. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004, 122:1175-1179. 10.1111/j.0022-202X.2004.22419.x, 15140220.
18. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, Maurer MH, Rossner M, Schneider A, Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004, 24:8237-8244. 10.1523/JNEUROSCI.1089-04.2004, 15385607.
19. Haile WB, Echeverry R, Wu J, Yepes M. The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 promotes the recruitment of neutrophils into the ischemic brain. J Cereb Blood Flow Metab 2010, 30:1147-1156. 10.1038/jcbfm.2009.280, 2949208, 20068578.
20. Inta I, Frauenknecht K, Dorr H, Kohlhof P, Rabsilber T, Auffarth GU, Burkly L, Mittelbronn M, Hahm K, Sommer C, Schwaninger M. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci 2008, 275:117-120. 10.1016/j.jns.2008.08.005, 18793781.
21. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425. 10.1038/nrd2488, 3018765, 18404150.
22. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999, 5:554-559. 10.1038/8432, 10229233.
23. Zhang X, Winkles JA, Gongora MC, Polavarapu R, Michaelson JS, Hahm K, Burkly L, Friedman M, Li XJ, Yepes M. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab 2007, 27:534-544. 10.1038/sj.jcbfm.9600368, 16835630.
24. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J, Yepes M. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience 2010, 171:1256-1264. 10.1016/j.neuroscience.2010.10.029, 2991428, 20955770.
25. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H. Multiple pathways of TWEAK-induced cell death. J Immunol 2002, 168:734-743.
26. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005, 280:3483-3492.
27. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med 2002, 8:1363-1368. 10.1038/nm1202-1363, 12457181.
28. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, Feuerstein GZ. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997, 28:1233-1244. 10.1161/01.STR.28.6.1233, 9183357.
29. Dawson DA, Martin D, Hallenbeck JM. Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 1996, 218:41-44. 10.1016/0304-3940(96)13116-5, 8939476.
30. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997, 778:265-271. 10.1016/S0006-8993(97)00981-5, 9459543.
31. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, Tschopp J, Wajant H. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999, 29:1785-1792. 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U, 10382740.
32. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997, 748:267-270. 10.1016/S0006-8993(96)01383-2, 9067475.
33. Ginis I, Schweizer U, Brenner M, Liu J, Azzam N, Spatz M, Hallenbeck JM. TNF-alpha pretreatment prevents subsequent activation of cultured brain cells with TNF-alpha and hypoxia via ceramide. Am J Physiol 1999, 276:C1171-C1183.
34. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997, 17:483-490.
35. Irving EA, Bamford M. Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab 2002, 22:631-647.
36. Nozaki K, Nishimura M, Hashimoto N. Mitogen-activated protein kinases and cerebral ischemia. Mol Neurobiol 2001, 23:1-19. 10.1385/MN:23:1:01, 11642541.
37. Hetman M, Gozdz A. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur J Biochem 2004, 271:2050-2055. 10.1111/j.1432-1033.2004.04133.x, 15153093.
38. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000, 79:355-369. 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0, 10972974.
39. Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD. Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res 1999, 833:181-190. 10.1016/S0006-8993(99)01528-0, 10375693.
40. Echeverry R, Wu J, Haile WB, Guzman J, Yepes M. Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest 2010, 120:2194-2205. 10.1172/JCI41722, 2877952, 20440070.
41. Kariko K, Weissman D, Welsh FA. Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 2004, 24:1288-1304.
42. Grabb MC, Choi DW. Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. J Neurosci 1999, 19:1657-1662.
43. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003, 170:341-348.
44. Saver JL. Time is brain--quantified. Stroke 2006, 37:263-266.
45. Fueller J, Becker M, Sienerth AR, Fischer A, Hotz C, Galmiche A. C-RAF activation promotes BAD poly-ubiquitylation and turn-over by the proteasome. Biochem Biophys Res Commun 2008, 370:552-556. 10.1016/j.bbrc.2008.03.141, 18402774.
46. Gary DS, Bruce-Keller AJ, Kindy MS, Mattson MP. Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J Cereb Blood Flow Metab 1998, 18:1283-1287.
47. Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, Cerami A, Probert L. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci USA 2008, 105:6185-6190. 10.1073/pnas.0801447105, 2299225, 18413601.